EA201692469A1 - Производное 2-ациламинотиазола или его соль - Google Patents

Производное 2-ациламинотиазола или его соль

Info

Publication number
EA201692469A1
EA201692469A1 EA201692469A EA201692469A EA201692469A1 EA 201692469 A1 EA201692469 A1 EA 201692469A1 EA 201692469 A EA201692469 A EA 201692469A EA 201692469 A EA201692469 A EA 201692469A EA 201692469 A1 EA201692469 A1 EA 201692469A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dysfunction
bladder
urinary
preventing
muscarinic
Prior art date
Application number
EA201692469A
Other languages
English (en)
Other versions
EA031866B1 (ru
Inventor
Тайсуке Такахаси
Таканори Койке
Кендзи Негоро
Хироаки Танака
Дзун Маеда
Казухиро Йокояма
Хадзиме Такамацу
Original Assignee
Астеллас Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Фарма Инк. filed Critical Астеллас Фарма Инк.
Publication of EA201692469A1 publication Critical patent/EA201692469A1/ru
Publication of EA031866B1 publication Critical patent/EA031866B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Предоставлено соединение, которое полезно в качестве активного ингредиента в фармацевтической композиции для профилактики или лечения дисфункции накопления мочи, дисфункции мочеиспускания, дисфункции нижних мочевыводящих путей и тому подобного. Авторы настоящего изобретения обнаружили, что производное тиазола, замещенное пиразинилкарбониламино в положении 2, является превосходным аллостерическим положительным модулятором мускаринового рецептора Ми предполагается в качестве средства для профилактики или лечения заболеваний мочевого пузыря/мочевыводящих путей, связанных с сокращением мочевого пузыря через посредство мускаринового рецептора М, таким образом, осуществив настоящее изобретение. Производное 2-ациламинотиазола или его соль по настоящему изобретению предполагается в качестве средства для профилактики или лечения заболеваний мочевого пузыря/мочевыводящих путей, связанных с сокращением мочевого пузыря через посредство мускаринового рецептора М, например дисфункции мочеиспускания, такой как гипоактивность мочевого пузыря.
EA201692469A 2014-06-06 2015-06-05 Производное 2-ациламинотиазола или его соль EA031866B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014118046 2014-06-06
PCT/JP2015/066321 WO2015186821A1 (ja) 2014-06-06 2015-06-05 2-アシルアミノチアゾール誘導体またはその塩

Publications (2)

Publication Number Publication Date
EA201692469A1 true EA201692469A1 (ru) 2017-05-31
EA031866B1 EA031866B1 (ru) 2019-03-29

Family

ID=54766887

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692469A EA031866B1 (ru) 2014-06-06 2015-06-05 Производное 2-ациламинотиазола или его соль

Country Status (34)

Country Link
US (2) USRE49111E1 (ru)
EP (1) EP3153511B1 (ru)
JP (1) JP6319436B2 (ru)
KR (1) KR102482844B1 (ru)
CN (2) CN110845490B (ru)
AR (1) AR100748A1 (ru)
AU (1) AU2015269449B2 (ru)
BR (1) BR112016028270B1 (ru)
CA (1) CA2950564C (ru)
CO (1) CO2017000044A2 (ru)
CY (1) CY1122290T1 (ru)
DK (1) DK3153511T3 (ru)
EA (1) EA031866B1 (ru)
ES (1) ES2732066T3 (ru)
HR (1) HRP20190943T1 (ru)
HU (1) HUE043496T2 (ru)
IL (1) IL249356B (ru)
LT (1) LT3153511T (ru)
MA (1) MA39950B1 (ru)
ME (1) ME03438B (ru)
MX (1) MX370140B (ru)
MY (1) MY197712A (ru)
NZ (1) NZ727142A (ru)
PH (1) PH12016502405A1 (ru)
PL (1) PL3153511T3 (ru)
PT (1) PT3153511T (ru)
RS (1) RS58809B1 (ru)
SA (1) SA516380427B1 (ru)
SG (2) SG10202000463YA (ru)
SI (1) SI3153511T1 (ru)
TR (1) TR201908676T4 (ru)
TW (2) TWI689507B (ru)
UA (1) UA122208C2 (ru)
WO (1) WO2015186821A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2744193B1 (en) 2006-12-20 2018-07-04 GVBB Holdings S.A.R.L Embedded audio routing switcher
PT3196200T (pt) 2014-08-26 2019-06-17 Astellas Pharma Inc Derivados de 2-aminotiazol ou sal do mesmo, como ligantes muscarínico m3 para o tratamento das doenças da bexiga
SI3555048T1 (sl) 2016-12-19 2021-11-30 Novartis Ag Novi derivati pikolinske kisline in njihova uporaba kot vmesne spojine
WO2019189766A1 (ja) * 2018-03-30 2019-10-03 持田製薬株式会社 新規ビアリールアミド誘導体
CN111718293A (zh) * 2019-03-18 2020-09-29 持田制药株式会社 双芳基酰胺衍生物的制造方法
EP3967311A1 (en) 2020-09-11 2022-03-16 Astellas Pharma Inc. Compounds for use in the treatment of dry mouth

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73543C2 (ru) 1999-12-07 2005-08-15 Тераванс, Інк. Производные мочевины, фармацевтическая композиция и применение производного при приготовлении лекарственного средства для лечения заболевания, которое опосредствуется мускариновым рецептором
JP2001278872A (ja) * 2000-03-27 2001-10-10 Banyu Pharmaceut Co Ltd 新規アミノチアゾール誘導体
WO2001090081A1 (en) * 2000-05-25 2001-11-29 F. Hoffmann-La Roche Ag Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
JPWO2003037862A1 (ja) 2001-10-30 2005-02-17 日本新薬株式会社 アミド誘導体及び医薬
JP4120586B2 (ja) 2002-01-18 2008-07-16 アステラス製薬株式会社 2−アシルアミノチアゾール誘導体又はその塩
TWI242478B (en) 2002-08-01 2005-11-01 Masami Nakamoto Metal nanoparticle and process for producing the same
TW200410951A (en) * 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
CA2529686C (en) 2003-07-17 2010-06-15 Astellas Pharma Inc. 2-acylaminothiazole derivative or salt thereof
JP4774995B2 (ja) * 2005-01-12 2011-09-21 アステラス製薬株式会社 アシルアミノチアゾール誘導体を有効成分とする医薬組成物
JP4665769B2 (ja) 2005-01-12 2011-04-06 アステラス製薬株式会社 アシルアミノチアゾール誘導体の製造法
CN101490003A (zh) * 2006-04-24 2009-07-22 阿斯利康(瑞典)有限公司 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物
WO2009054468A1 (ja) * 2007-10-24 2009-04-30 Astellas Pharma Inc. アゾールカルボキサミド化合物又はその塩
KR101764952B1 (ko) 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ampk-활성화 헤테로시클릭 화합물 및 그의 사용 방법
TWI647227B (zh) * 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 2-醯胺噻唑衍生物或其鹽

Also Published As

Publication number Publication date
CN106414438A (zh) 2017-02-15
CN106414438B (zh) 2019-12-31
AR100748A1 (es) 2016-10-26
SI3153511T1 (sl) 2019-08-30
CN110845490A (zh) 2020-02-28
CA2950564A1 (en) 2015-12-10
AU2015269449B2 (en) 2019-03-14
AU2015269449A1 (en) 2016-12-22
IL249356A0 (en) 2017-02-28
SA516380427B1 (ar) 2019-11-28
KR102482844B1 (ko) 2022-12-30
DK3153511T3 (da) 2019-06-24
RS58809B1 (sr) 2019-07-31
SG10202000463YA (en) 2020-02-27
TWI745877B (zh) 2021-11-11
HRP20190943T1 (hr) 2019-09-20
JP6319436B2 (ja) 2018-05-09
ES2732066T3 (es) 2019-11-20
US9951060B2 (en) 2018-04-24
EP3153511A1 (en) 2017-04-12
MX370140B (es) 2019-12-03
TW201613914A (en) 2016-04-16
PL3153511T3 (pl) 2019-09-30
MX2016016134A (es) 2017-03-08
LT3153511T (lt) 2019-07-10
CY1122290T1 (el) 2021-01-27
ME03438B (me) 2020-01-20
EP3153511A4 (en) 2017-12-06
MY197712A (en) 2023-07-09
CN110845490B (zh) 2023-03-28
MA39950B1 (fr) 2019-08-30
PH12016502405B1 (en) 2017-02-20
TWI689507B (zh) 2020-04-01
EA031866B1 (ru) 2019-03-29
EP3153511B1 (en) 2019-05-15
JPWO2015186821A1 (ja) 2017-04-20
BR112016028270A8 (pt) 2023-01-17
BR112016028270A2 (pt) 2022-07-19
PH12016502405A1 (en) 2017-02-20
NZ727142A (en) 2022-10-28
PT3153511T (pt) 2019-06-28
TW202026294A (zh) 2020-07-16
CA2950564C (en) 2023-03-07
US20170197955A1 (en) 2017-07-13
WO2015186821A1 (ja) 2015-12-10
BR112016028270B1 (pt) 2023-05-02
MA39950A (fr) 2017-04-12
KR20170013987A (ko) 2017-02-07
USRE49111E1 (en) 2022-06-21
SG11201610201UA (en) 2017-01-27
CO2017000044A2 (es) 2017-03-31
IL249356B (en) 2019-11-28
TR201908676T4 (tr) 2019-07-22
UA122208C2 (uk) 2020-10-12
HUE043496T2 (hu) 2019-08-28

Similar Documents

Publication Publication Date Title
EA201692469A1 (ru) Производное 2-ациламинотиазола или его соль
EA201591391A1 (ru) Производное 2-ациламинотиазола или его соль
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
EA201790785A1 (ru) Производные тетрагидроизохинолина
MA41041A (fr) Dérivés de benzothiazole substitués utilisés en tant qu'agonistes de gpr40 pour le traitement du diabète de type ii
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
EA201791696A1 (ru) Композиция для лечения веноокклюзионной болезни печени
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
EA201692298A1 (ru) Производные карбоксамидов
MA49152A (fr) Schémas posologiques d'immunoconjugués anti-cd33
EA201990095A1 (ru) КОНДЕНСИРОВАННЫЕ ТИОФЕНОВЫЕ ПРОИЗВОДНЫЕ, ПРИЕМЛЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NAPI-IIb
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
MA46759A (fr) Dosage de conjugués anticorps-médicament anti-cd30 pour humain non adulte
BR112017018192A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica.
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
BR112018002138A2 (pt) composto 2-(5 s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida, uso, composição farmacêutica e método para a profilaxia ou o tratamento de convulsões
CL2017000026A1 (es) Formas de dosificación farmacéutica
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
TR201908031T4 (tr) İdrar kesesi hastalıklarının tedavisine yönelik muskarinik m3 ligandları olarak 2-aminotiyazol türevleri veya bunların tuzu.
IT201600084488A1 (it) Composizione per trattamento di patologie dell'apparato urinario

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): TM